Medicinal products for treatment of migraine: study assortment, socio-economic accessibility and consumption in Ukraine
DOI:
https://doi.org/10.24959/uekj.19.7Keywords:
drugs for the treatment of migraine, assortment, drug consumption, socio-economic accessibilityAbstract
Migraine refers to diseases that have important medico-social significance associated with intermittent attacks of severe pulsating pain, the risk of complications, reduced quality of life for patients, high total cost and duration of treatment.
Aim. To analysis of the range, assessment of indicators of socio-economic availability and consumption of drugs for the treatment of migraine in the Ukrainian pharmaceutical market during 2014-2016.
Materials and methods. To analyse the socio-economic availability of drugs for the treatment of migraine, solvency adequacy indicators (Ca.s.) were calculated, which show the wages proportion spent on medicines purchasing per monthly course treatment of migraine. Indicators DDDs/1000 habitants /day or DIDs were used to calculate the drugs consumption for the treatment of migraine.
Results. During 2014-2016, migraine drugs were introduced to the market in a limited range of 20-33 Trade Names based on 3-4 INN. The vast majority of medicines range on the market belonged to sumatriptan (43-65 %). The prices of drugs varied in a wide range, but grew every year. Among the medications for the treatment of migraine, medium-available (51-74 %) and inaccessible (26-49 %) prevailed and only one ergotamine was available in 2016. The total consumption of all drugs on the market was 0.1998 DID (2014) 0.1334 DID (2015) 0.3211 DID (2016), respectively. The highest consumption figures are set for sumatriptan preparations, represented in a larger number of more accessible trade names for the population of Ukraine.
Conclusions. The Ukrainian pharmaceutical market has a limited assortment of drugs for the treatment of migraine in Ukraine. Indicators of socio-economic availability and consumption of drugs for the treatment of migraine are generally quite low, which may be due to the significant cost of treatment with drugs in this group.
References
Bozhenko, N. L. (2016). Liky Ukrayiny. 4 (200), 52–60.
Oros, M. M. & Hlavats’kykh, Kh. S. (2018). Ukrayins’kyy medychnyy chasopys. 1 (123). https://doi.org/10.32471/umj.1680-3051.123.120210
Stepanchenko, A. V. (2009). Doktor, 1, 68–70.4.
Danilov, A. (2011). Diagnostika i lechenie golovnoi boli. Moscow, 111.
Pukhalska, T. H., Kolosova, O. A., Osypova, V. V., Vein, A. M. (2012). Klinichna farmakolohiia i terapiia, 3, 88–92.
Mishchenko, T. S. (2010). Zdorove Ukrainy, 2(13), 7–9.
Brown, J. S., Papadopoulos, G., Neumann, P. J., Friedman, M., Miller, J. D., & Menzin, J. (2005). Cost-Effectiveness of Topiramate in Migraine Prevention: Results From a Pharmacoeconomic Model of Topiramate Treatment. Headache: The Journal of Head and Face Pain, 45(8), 1012–1022. https://doi.org/10.1111/j.1526-4610.2005.05182.x
Mnushko, Z. M., Karam Akhmed, Sofronova, I. V. (2010). Ukrainskyi zhurnal klinichnoi ta laboratornoi medytsyny, 5 (2), 53–57.
Prohramnyi kompleks «Apteka» kompanii «Morion». (n.d.). Available at: http://pharmbase.com.ua/ru/
Yakovlieva, L. V., Mishchenko, O. Ya., Adonkina, V. Yu. (2017). Farmakoepidemiolohichni doslidzhennia obsiahiv spozhyvannia antyhipertenzyvnykh likarskykh zasobiv v Ukraini: monohrafiia. Kharkiv: NFaU, 108.
Derzhavna sluzhba statystyky Ukrayiny [Elektronnyy resurs]. (n.d.). Available at: www.ukrstat.gov.ua
Morozov, A. M., Yakovlyeva, L. V., Stepanenko, A. V. (2013). Vyvchennya spozhyvannya likars’kykh zasobiv za anatomo-terapevtychno-khimichnoyu klasyfikatsiyeyu ta vstanovlenymy dobovymy dozamy : metod. rek. Kharkiv, 34.
Koreshkina, M. I. (2011). Zhurnal nevrologii i psikhiatrii im S.S. Korsakova, 111 (9), 25–31.
Hall, G. C., Brown, M. M., Mo, J., & MacRae, K. D. (2004). Triptans in migraine: The risks of stroke, cardiovascular disease, and death in practice. Neurology, 62(4), 563–568. https://doi.org/10.1212/01.wnl.0000110312.36809.7f
Gallagher, R. M., Dennish, G., Spierings, E. L. H., & Chitra, R. (2000). A Comparative Trial of Zolmitriptan and Sumatriptan for the Acute Oral Treatment of Migraine. Headache: The Journal of Head and Face Pain, 40(2), 119–128. https://doi.org/10.1046/j.1526-4610.2000.00017.x
Christie, S., Göbel, H., Mateos, V., Allen, C., Vrijens, F., & Shivaprakash, M. (2002). Crossover Comparison of Efficacy and Preference for Rizatriptan 10 mg versus Ergotamine/Caffeine in Migraine. European Neurology, 49(1), 20–29. https://doi.org/10.1159/000067018
Downloads
Published
Issue
Section
License
Copyright (c) 2019 National University of Pharmacy
This work is licensed under a Creative Commons Attribution 4.0 International License.
Authors who publish with this journal agree to the following terms:- Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.
- Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.
- Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See The Effect of Open Access).
